tat-59 and fosphenytoin
tat-59 has been researched along with fosphenytoin* in 2 studies
Other Studies
2 other study(ies) available for tat-59 and fosphenytoin
Article | Year |
---|---|
Absorption rate limit considerations for oral phosphate prodrugs.
To evaluate the potential of phosphate ester prodrugs to significantly improve the absorptive flux of poorly soluble parent drugs.. Absorptive transport studies of parent drugs and their prodrugs were carried out in Caco-2 cells. Prodrugs of parent drugs with variable aqueous solubilities were tested: Hydrocortisone-phosphate/Hydrocortisone, Fosphenytoin/phenytoin, TAT-59/DP-TAT-59, and Entacapone phosphate/Entacapone. Additional absorption studies were carried out in rats.. Absorptive fluxes of DP-TAT-59 and phenytoin increased 9.8 or 3.3-fold after dosing TAT-59 and 500 microM fosphenytoin, respectively. Hydrocortisone's flux did not increase with hydrocortisone-phosphate at 100 microM. Permeability of the highly lipophilic and protein bound compound, DP-TAT-59, was significantly increased with serosal albumin. No permeability increase was observed for the other drugs with albumin. Entacapone phosphate failed to improve the flux of entacapone compared to an entacapone solution, but the prodrug solution did yield higher entacapone plasma levels in rats when compared with an entacapone suspension.. Ideal phosphate prodrug candidates are characterized by high permeability and low solubility (BCS Class II drugs). For low dose BCS Class II drug candidates, however, no biopharmaceutical advantage may be gained. Phosphate prodrugs of parent drugs with limited permeability may fail. When screening highly lipophilic parent drugs transport studies should be done with albumin. Topics: Administration, Oral; Algorithms; Animals; Area Under Curve; Biological Transport, Active; Caco-2 Cells; Catechols; Chemical Phenomena; Chemistry, Physical; Humans; Hydrocortisone; Hydrogen-Ion Concentration; In Vitro Techniques; Intestinal Absorption; Intestinal Mucosa; Jejunum; Male; Nitriles; Perfusion; Permeability; Phenytoin; Prodrugs; Rats; Rats, Wistar; Tamoxifen | 2003 |
Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs.
Many oral phosphate prodrugs have failed to improve the rate or extent of absorption compared to their insoluble parent drugs. Rapid parent drug generation via intestinal alkaline phosphatase can result in supersaturated solutions, leading to parent drug precipitation. The purpose was to (1) investigate whether parent drugs can precipitate from prodrug solutions in presence of alkaline phosphatase; (2) determine whether induction times are influenced by (a) dephosphorylation rate, (b) parent drug supersaturation level, and (c) parent drug solubility. Induction times were determined from increases in optical densities after enzyme addition to prodrug solutions of TAT-59, fosphenytoin and estramustine phosphate. Apparent supersaturation ratios (sigma) were calculated from parent drug solubility at intestinal pH. Precipitation could be generated for all three prodrugs. Induction times decreased with increased enzyme activity and supersaturation level and were within gastrointestinal residence times for TAT-59 concentration>/=21microM (sigma>/=210). Induction times for fosphenytoin were less than the GI residence time (199min) for concentrations of approximately 352 microM (sigma=4.0). At approximately 475 microM (sigma=5.3) the induction times were less than 90min. For estramustine-phosphate, no precipitation was observed within GI residence times. Enzyme-mediated precipitation will depend on apparent supersaturation ratios, parent drug dose, solubility and solubilization by the prodrug. Topics: Alkaline Phosphatase; Caco-2 Cells; Chemical Precipitation; Chromatography, High Pressure Liquid; Crystallization; Drug Stability; Estramustine; Humans; Mass Spectrometry; Organophosphates; Phenytoin; Prodrugs; Solubility; Tamoxifen | 2003 |